You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameTemozolomide
Accession NumberDB00853  (APRD00557)
TypeSmall Molecule
GroupsApproved, Investigational
Description

Temozolomide (Temodar and Temodal) is an oral alkylating agent used for the treatment of refractory anaplastic astrocytoma - a type of cancerous brain tumor. Temozolomide is not active until it is converted at physiologic pH to the active form, 5(3-methyltriazen-1-yl)imidazole-4-carboxamide (MTIC).

Structure
Thumb
Synonyms
3-Methyl-4-oxo-3,4-dihydroimidazo(5,1-D)(1,2,3,5)tetrazine-8-carboxamide
3,4-dihydro-3-Methyl-4-oxoimidazo(5,1-D)-1,2,3,5-tetrazine-8-carboxamide
3,4-dihydro-3-Methyl-4-oxoimidazo(5,1-D)-as-tetrazine-8-carboxamide
8-Carbamoyl-3-methylimidazo(5,1-D)-1,2,3,5-tetrazin-4(3H)-one
BRN 5547136
CCRG 81045
CCRG-81045
CCRIS 8996
m & b 39831
M&B 39831
MB 39831
Methazolastone
NSC 362856
Sch 52365
Temodal
Temodar
Temozolodida
Temozolomid
Temozolomida
Témozolomide
Temozolomidum
TMZ
External Identifiers
  • BRN 5547136
  • CCRG 81045
  • M & B 39831
  • NSC 362856
  • SCH 52365
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Ach-temozolomidecapsule140 mgoralAccord Healthcare Inc2012-07-25Not applicableCanada
Ach-temozolomidecapsule5 mgoralAccord Healthcare Inc2016-01-13Not applicableCanada
Ach-temozolomidecapsule100 mgoralAccord Healthcare Inc2012-07-25Not applicableCanada
Ach-temozolomidecapsule20 mgoralAccord Healthcare Inc2012-07-25Not applicableCanada
Ach-temozolomidecapsule250 mgoralAccord Healthcare Inc2012-07-25Not applicableCanada
Ach-temozolomidecapsule180 mgoralAccord Healthcare Inc2012-07-25Not applicableCanada
Act Temozolomidecapsule180 mgoralActavis Pharma CompanyNot applicableNot applicableCanada
Act Temozolomidecapsule250 mgoralActavis Pharma Company2012-11-07Not applicableCanada
Act Temozolomidecapsule140 mgoralActavis Pharma Company2012-11-07Not applicableCanada
Act Temozolomidecapsule100 mgoralActavis Pharma Company2012-11-07Not applicableCanada
Act Temozolomidecapsule20 mgoralActavis Pharma Company2012-11-07Not applicableCanada
Act Temozolomidecapsule5 mgoralActavis Pharma Company2015-12-08Not applicableCanada
Taro-temozolomidecapsule180 mgoralTaro Pharmaceuticals IncNot applicableNot applicableCanada
Taro-temozolomidecapsule250 mgoralTaro Pharmaceuticals Inc2015-07-23Not applicableCanada
Taro-temozolomidecapsule140 mgoralTaro Pharmaceuticals Inc2015-07-23Not applicableCanada
Taro-temozolomidecapsule100 mgoralTaro Pharmaceuticals Inc2015-07-23Not applicableCanada
Taro-temozolomidecapsule20 mgoralTaro Pharmaceuticals Inc2015-07-23Not applicableCanada
Taro-temozolomidecapsule5 mgoralTaro Pharmaceuticals Inc2015-07-23Not applicableCanada
Temodalcapsule180 mgoralMerck Canada Inc2009-02-212011-07-22Canada
Temodalcapsule140 mgoralMerck Canada Inc2009-02-21Not applicableCanada
Temodalcapsule250 mgoralMerck Canada Inc1999-11-12Not applicableCanada
Temodalcapsule100 mgoralMerck Canada Inc1999-11-12Not applicableCanada
Temodalcapsule20 mgoralMerck Canada Inc1999-11-12Not applicableCanada
Temodalcapsule5 mgoralMerck Canada Inc1999-11-12Not applicableCanada
Temodalpowder for solution100 mgintravenousMerck Canada Inc2009-12-102016-02-01Canada
Temodarcapsule250 mg/1oralPhysicians Total Care, Inc.2006-04-13Not applicableUs
Temodarcapsule100 mg/1oralMerck Sharp & Dohme Corp.1999-08-11Not applicableUs
Temodarcapsule180 mg/1oralPhysicians Total Care, Inc.2009-01-26Not applicableUs
Temodarcapsule100 mg/1oralPhysicians Total Care, Inc.2005-10-07Not applicableUs
Temodarcapsule5 mg/1oralPhysicians Total Care, Inc.2005-10-20Not applicableUs
Temodarcapsule5 mg/1oralMerck Sharp & Dohme Corp.1999-08-11Not applicableUs
Temodarcapsule20 mg/1oralPhysicians Total Care, Inc.2005-06-29Not applicableUs
Temodarcapsule20 mg/1oralMerck Sharp & Dohme Corp.1999-08-11Not applicableUs
Temodarcapsule180 mg/1oralMerck Sharp & Dohme Corp.1999-08-11Not applicableUs
Temodarcapsule140 mg/1oralMerck Sharp & Dohme Corp.1999-08-11Not applicableUs
Temodarcapsule250 mg/1oralMerck Sharp & Dohme Corp.1999-08-11Not applicableUs
Temodarinjection, powder, lyophilized, for solution2.5 mg/mLintravenousMerck Sharp & Dohme Corp.2009-02-27Not applicableUs
Temozolomidecapsule20 mg/1oralSandoz Inc.2013-08-12Not applicableUs
Temozolomidecapsule5 mg/1oralSandoz Inc.2013-08-12Not applicableUs
Temozolomidecapsule250 mg/1oralSandoz Inc.2013-08-12Not applicableUs
Temozolomidecapsule180 mg/1oralSandoz Inc.2013-08-12Not applicableUs
Temozolomidecapsule140 mg/1oralSandoz Inc.2013-08-12Not applicableUs
Temozolomidecapsule100 mg/1oralSandoz Inc.2013-08-12Not applicableUs
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-temozolomidecapsule250 mgoralApotex IncNot applicableNot applicableCanada
Apo-temozolomidecapsule180 mgoralApotex IncNot applicableNot applicableCanada
Apo-temozolomidecapsule140 mgoralApotex IncNot applicableNot applicableCanada
Apo-temozolomidecapsule100 mgoralApotex IncNot applicableNot applicableCanada
Apo-temozolomidecapsule20 mgoralApotex IncNot applicableNot applicableCanada
Apo-temozolomidecapsule5 mgoralApotex IncNot applicableNot applicableCanada
Temozolomidecapsule180 mg/1oralAmneal Pharmaceuticals of New York, LLC2015-04-03Not applicableUs
Temozolomidecapsule100 mg/1oralRoxane Laboratories, Inc.2016-03-24Not applicableUs
Temozolomidecapsule100 mg/1oralSun Pharma Global FZE2014-02-13Not applicableUs
Temozolomidecapsule5 mg/1oralKremers Urban Pharmaceuticals Inc.2016-02-10Not applicableUs
Temozolomidecapsule5 mg/1oralTeva Pharmaceuticals USA Inc2013-08-12Not applicableUs
Temozolomidecapsule250 mg/1oralAmneal Pharmaceuticals of New York, LLC2015-04-03Not applicableUs
Temozolomidecapsule250 mg/1oralLannett Company, Inc.2016-03-23Not applicableUs
Temozolomidecapsule140 mg/1oralRoxane Laboratories, Inc.2016-03-24Not applicableUs
Temozolomidecapsule20 mg/1oralRoxane Laboratories, Inc.2016-03-24Not applicableUs
Temozolomidecapsule20 mg/1oralSun Pharma Global FZE2014-02-13Not applicableUs
Temozolomidecapsule180 mg/1oralLannett Company, Inc.2016-03-23Not applicableUs
Temozolomidecapsule140 mg/1oralAmneal Pharmaceuticals of New York, LLC2015-04-03Not applicableUs
Temozolomidecapsule140 mg/1oralLannett Company, Inc.2016-03-23Not applicableUs
Temozolomidecapsule100 mg/1oralAmneal Pharmaceuticals of New York, LLC2015-04-03Not applicableUs
Temozolomidecapsule5 mg/1oralRoxane Laboratories, Inc.2016-03-24Not applicableUs
Temozolomidecapsule5 mg/1oralSun Pharma Global FZE2014-02-13Not applicableUs
Temozolomidecapsule100 mg/1oralLannett Company, Inc.2016-03-23Not applicableUs
Temozolomidecapsule20 mg/1oralAmneal Pharmaceuticals of New York, LLC2015-04-03Not applicableUs
Temozolomidecapsule250 mg/1oralKremers Urban Pharmaceuticals Inc.2016-02-10Not applicableUs
Temozolomidecapsule180 mg/1oralTeva Pharmaceuticals USA Inc2013-08-12Not applicableUs
Temozolomidecapsule20 mg/1oralLannett Company, Inc.2016-03-23Not applicableUs
Temozolomidecapsule5 mg/1oralAmneal Pharmaceuticals of New York, LLC2015-04-03Not applicableUs
Temozolomidecapsule180 mg/1oralKremers Urban Pharmaceuticals Inc.2016-02-10Not applicableUs
Temozolomidecapsule140 mg/1oralTeva Pharmaceuticals USA Inc2013-08-12Not applicableUs
Temozolomidecapsule5 mg/1oralLannett Company, Inc.2016-03-23Not applicableUs
Temozolomidecapsule180 mg/1oralSun Pharma Global FZE2014-02-13Not applicableUs
Temozolomidecapsule140 mg/1oralKremers Urban Pharmaceuticals Inc.2016-02-10Not applicableUs
Temozolomidecapsule250 mg/1oralTeva Pharmaceuticals USA Inc2013-08-12Not applicableUs
Temozolomidecapsule140 mg/1oralSun Pharma Global FZE2014-02-13Not applicableUs
Temozolomidecapsule100 mg/1oralKremers Urban Pharmaceuticals Inc.2016-02-10Not applicableUs
Temozolomidecapsule100 mg/1oralTeva Pharmaceuticals USA Inc2013-08-12Not applicableUs
Temozolomidecapsule250 mg/1oralRoxane Laboratories, Inc.2016-03-24Not applicableUs
Temozolomidecapsule250 mg/1oralSun Pharma Global FZE2014-02-13Not applicableUs
Temozolomidecapsule20 mg/1oralKremers Urban Pharmaceuticals Inc.2016-02-10Not applicableUs
Temozolomidecapsule20 mg/1oralTeva Pharmaceuticals USA Inc2013-08-12Not applicableUs
Temozolomidecapsule140 mg/1oralAvera Mc Kennan Hospital2015-06-11Not applicableUs
Temozolomidecapsule180 mg/1oralRoxane Laboratories, Inc.2016-03-24Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
UNIIYF1K15M17Y
CAS number85622-93-1
WeightAverage: 194.1508
Monoisotopic: 194.055223466
Chemical FormulaC6H6N6O2
InChI KeyInChIKey=BPEGJWRSRHCHSN-UHFFFAOYSA-N
InChI
InChI=1S/C6H6N6O2/c1-11-6(14)12-2-8-3(4(7)13)5(12)9-10-11/h2H,1H3,(H2,7,13)
IUPAC Name
3-methyl-4-oxo-3H,4H-imidazo[4,3-d][1,2,3,5]tetrazine-8-carboxamide
SMILES
CN1N=NC2=C(N=CN2C1=O)C(N)=O
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as imidazotetrazines. These are organic polycyclic compounds containing an imidazole ring fused to a tetrazine ring. Imidazole is 5-membered ring consisting of three carbon atoms, and two nitrogen centers at the 1- and 3-positions. Tetrazine is a six-membered aromatic heterocycle made up of four nitrogen atoms and a two carbon atoms.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassImidazotetrazines
Sub ClassNot Available
Direct ParentImidazotetrazines
Alternative Parents
Substituents
  • Imidazotetrazine
  • Tetrazine
  • N-substituted imidazole
  • Heteroaromatic compound
  • Vinylogous amide
  • Imidazole
  • Azole
  • Primary carboxylic acid amide
  • Carboxamide group
  • Azacycle
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors
Pharmacology
IndicationFor the treatment of adult patients diagnosed with anaplastic astrocytoma whose disease has progressed after therapy with nitrosourea and procarbazine, as well as concomitantly with radiation therapy for treatment of newly diagnosed glioblastoma multiforme. Also used as maintenance therapy for glioblastoma multiforme.
PharmacodynamicsTemozolomide is an imidazotetrazine deritave and an antineoplastic agent. It is a prodrug that has little to no pharmacological activity until it is hydrolyzed in vivo to 5-(3-methyltriazen-1-yl)imidazole-4-carboxamide (MTIC). After administration, temozolomide undergoes rapid, nonenzymatic hydrolysis at physiological pH to MTIC, which is the active form of the drug. MTIC is generated through the effect of water at the highly electropositive C4 position of temozolomide, causing the ring of temozolomide to open, release carbon dioxide, and generate MTIC.
Mechanism of actionTemozolomide is not active until it is converted at physiologic pH to MTIC. It is suggested that MTIC then alkylates DNA at the N7 position of guanine, O3 position of adenosine, and O6 position of guanosine, with the most common site being the N7 position. This methylation of guanine residues lead to single and double-strand DNA breaks and subsequent apoptotic cell death. It is suggested that the N7-methylguanine plays a critical role in the antitumor activity of the drug, as there is a correlation between the sensitivity of tumor cell lines to temozolomide and the activity of O6-alkylguanine alkyltransferase, which is the DNA repair protein that specifically removes alkyl groups at the O6 position of guanine. Cells lines that have lower levels of AGT are more sensitive to the cytotoxicity of temozolomide. It is also suggested that cytotoxic mechanism of temozolomide is related to the failure of the DNA MMR system to find a complementary base for methylated guanine. The DNA MMR system is involved in the formation of a number of proteins that remove methylated guanine. Evidence shows that when this repair process is targeted to the DNA strand opposite the O6-methylguanine, its inability to find the correct target leads to long-lived nicks in the DNA. The accumulation of these nicks lead to the inhibition of replication in the daughter cells, thereby blocking the cell cycle at the G2-M boundary.
Related Articles
AbsorptionRapid and complete absorption in the gastrointestinal tract
Volume of distribution
  • 0.4 L/kg
Protein binding15%
MetabolismNot Available
Route of eliminationAbout 38% of the administered temozolomide total radioactive dose is recovered over 7 days: 37.7% in urine and 0.8% in feces.
Half lifeApproximately 1.8 hours.
Clearance
  • 5.5 L/hr/m2
ToxicityNot Available
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9879
Caco-2 permeable+0.5608
P-glycoprotein substrateNon-substrate0.7228
P-glycoprotein inhibitor INon-inhibitor0.9255
P-glycoprotein inhibitor IINon-inhibitor0.9823
Renal organic cation transporterNon-inhibitor0.8822
CYP450 2C9 substrateNon-substrate0.7948
CYP450 2D6 substrateNon-substrate0.8695
CYP450 3A4 substrateNon-substrate0.5855
CYP450 1A2 substrateNon-inhibitor0.8134
CYP450 2C9 inhibitorNon-inhibitor0.9753
CYP450 2D6 inhibitorNon-inhibitor0.9479
CYP450 2C19 inhibitorNon-inhibitor0.9522
CYP450 3A4 inhibitorNon-inhibitor0.9571
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9954
Ames testNon AMES toxic0.5322
CarcinogenicityNon-carcinogens0.9412
BiodegradationNot ready biodegradable0.5172
Rat acute toxicity2.5279 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.7553
hERG inhibition (predictor II)Non-inhibitor0.9242
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Schering corp
  • Barr laboratories inc
Packagers
Dosage forms
FormRouteStrength
Capsuleoral180 mg
Capsuleoral100 mg
Capsuleoral140 mg
Capsuleoral20 mg
Capsuleoral250 mg
Capsuleoral5 mg
Powder for solutionintravenous100 mg
Capsuleoral100 mg/1
Capsuleoral140 mg/1
Capsuleoral180 mg/1
Capsuleoral20 mg/1
Capsuleoral250 mg/1
Capsuleoral5 mg/1
Injection, powder, lyophilized, for solutionintravenous2.5 mg/mL
Prices
Unit descriptionCostUnit
Temodar 250 mg capsule466.11USD capsule
Temodar 180 mg capsule401.53USD capsule
Temodar 100 mg capsule223.07USD capsule
Temodar 20 mg capsule44.62USD capsule
Temodar 5 mg capsule10.84USD capsule
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA2066313 No2002-08-202012-04-16Canada
CA2476494 No2010-04-272023-02-20Canada
US5260291 No1993-08-112013-08-11Us
US6987108 No2003-09-082023-09-08Us
US7786118 No2003-02-212023-02-21Us
US8623868 No2003-02-212023-02-21Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point212 °CNot Available
logP-2.8Not Available
Predicted Properties
PropertyValueSource
Water Solubility5.09 mg/mLALOGPS
logP-1ALOGPS
logP-0.28ChemAxon
logS-1.6ALOGPS
pKa (Strongest Acidic)10.51ChemAxon
pKa (Strongest Basic)-3.6ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area105.94 Å2ChemAxon
Rotatable Bond Count1ChemAxon
Refractivity47.86 m3·mol-1ChemAxon
Polarizability16.88 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
References
Synthesis Reference

Shen-Chun Kuo, “Synthesis of temozolomide and analogs.” U.S. Patent US20020133006, issued September 19, 2002.

US20020133006
General References
  1. Neyns B, Tosoni A, Hwu WJ, Reardon DA: Dose-dense temozolomide regimens: antitumor activity, toxicity, and immunomodulatory effects. Cancer. 2010 Jun 15;116(12):2868-77. doi: 10.1002/cncr.25035. [PubMed:20564393 ]
  2. Wick W, Platten M, Weller M: New (alternative) temozolomide regimens for the treatment of glioma. Neuro Oncol. 2009 Feb;11(1):69-79. doi: 10.1215/15228517-2008-078. Epub 2008 Sep 4. [PubMed:18772354 ]
  3. Villano JL, Seery TE, Bressler LR: Temozolomide in malignant gliomas: current use and future targets. Cancer Chemother Pharmacol. 2009 Sep;64(4):647-55. doi: 10.1007/s00280-009-1050-5. Epub 2009 Jun 19. [PubMed:19543728 ]
  4. Meije Y, Lizasoain M, Garcia-Reyne A, Martinez P, Rodriguez V, Lopez-Medrano F, Juan RS, Lalueza A, Aguado JM: Emergence of cytomegalovirus disease in patients receiving temozolomide: report of two cases and literature review. Clin Infect Dis. 2010 Jun 15;50(12):e73-6. doi: 10.1086/653011. [PubMed:20455691 ]
  5. Trinh VA, Patel SP, Hwu WJ: The safety of temozolomide in the treatment of malignancies. Expert Opin Drug Saf. 2009 Jul;8(4):493-9. doi: 10.1517/14740330902918281 . [PubMed:19435405 ]
  6. Yung WK: Temozolomide in malignant gliomas. Semin Oncol. 2000 Jun;27(3 Suppl 6):27-34. [PubMed:10866347 ]
  7. Friedman HS, Kerby T, Calvert H: Temozolomide and treatment of malignant glioma. Clin Cancer Res. 2000 Jul;6(7):2585-97. [PubMed:10914698 ]
  8. Mutter N, Stupp R: Temozolomide: a milestone in neuro-oncology and beyond? Expert Rev Anticancer Ther. 2006 Aug;6(8):1187-204. [PubMed:16925485 ]
External Links
ATC CodesL01AX03
AHFS Codes
  • 10:00.00
PDB EntriesNot Available
FDA labelDownload (67.2 KB)
MSDSDownload (58 KB)
Interactions
Drug Interactions
Drug
ClozapineThe risk or severity of adverse effects can be increased when Temozolomide is combined with Clozapine.
DenosumabThe risk or severity of adverse effects can be increased when Denosumab is combined with Temozolomide.
LeflunomideThe risk or severity of adverse effects can be increased when Temozolomide is combined with Leflunomide.
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Temozolomide.
NatalizumabThe risk or severity of adverse effects can be increased when Temozolomide is combined with Natalizumab.
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Temozolomide.
RoflumilastRoflumilast may increase the immunosuppressive activities of Temozolomide.
Sipuleucel-TThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Temozolomide.
TacrolimusThe risk or severity of adverse effects can be increased when Tacrolimus is combined with Temozolomide.
TofacitinibTemozolomide may increase the immunosuppressive activities of Tofacitinib.
TrastuzumabTrastuzumab may increase the neutropenic activities of Temozolomide.
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Temozolomide.
Food InteractionsNot Available

Targets

1. DNA
Kind
Nucleotide
Organism
Human
Pharmacological action
yes
Actions
cross-linking/alkylation
General Function:
Used for biological information storage.
Specific Function:
DNA contains the instructions needed for an organism to develop, survive and reproduce.
Molecular Weight:
2.15 x 1012 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Zaremba T, Curtin NJ: PARP inhibitor development for systemic cancer targeting. Anticancer Agents Med Chem. 2007 Sep;7(5):515-23. [PubMed:17896912 ]
  4. Dinca EB, Sarkaria JN, Schroeder MA, Carlson BL, Voicu R, Gupta N, Berger MS, James CD: Bioluminescence monitoring of intracranial glioblastoma xenograft: response to primary and salvage temozolomide therapy. J Neurosurg. 2007 Sep;107(3):610-6. [PubMed:17886562 ]
  5. Marchesi F, Turriziani M, Tortorelli G, Avvisati G, Torino F, De Vecchis L: Triazene compounds: mechanism of action and related DNA repair systems. Pharmacol Res. 2007 Oct;56(4):275-87. Epub 2007 Aug 9. [PubMed:17897837 ]
  6. Neyns B, Tosoni A, Hwu WJ, Reardon DA: Dose-dense temozolomide regimens: antitumor activity, toxicity, and immunomodulatory effects. Cancer. 2010 Jun 15;116(12):2868-77. doi: 10.1002/cncr.25035. [PubMed:20564393 ]
  7. Wick W, Platten M, Weller M: New (alternative) temozolomide regimens for the treatment of glioma. Neuro Oncol. 2009 Feb;11(1):69-79. doi: 10.1215/15228517-2008-078. Epub 2008 Sep 4. [PubMed:18772354 ]
  8. Natelson EA, Pyatt D: Temozolomide-induced myelodysplasia. Adv Hematol. 2010;2010:760402. doi: 10.1155/2010/760402. Epub 2010 Mar 4. [PubMed:20224797 ]
  9. Friedman HS, Kerby T, Calvert H: Temozolomide and treatment of malignant glioma. Clin Cancer Res. 2000 Jul;6(7):2585-97. [PubMed:10914698 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inducer
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on June 28, 2016 01:52